Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S Submit New Drug Application In The US For Brexpiprazole For The Treatment Of Schizophrenia And As Adjunctive Therapy For The Treatment Of Major Depressive Disorder

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TOKYO & COPENHAGEN, Denmark--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S, today announced the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for brexpiprazole for the treatment of schizophrenia and as adjunctive treatment of major depressive disorder (MDD).

Help employers find you! Check out all the jobs and post your resume.

Back to news